Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 19.31 is 434% above its 5-year average of 3.62, near the high end of its 5-year range (0.33–22.61).
As of the fiscal period ended Tuesday, June 30, 2026. 56.14% above its 12-month average of 12.36.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 19.31.
CURRENT RATIO
19.31
CURRENT RATIO AVG TTM
12.36
CURRENT RATIO AVG 3Y
8.58
CURRENT RATIO AVG 5Y
3.62
CURRENT RATIO AVG 10Y
1.67
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+56.14%
CURRENT VS 3Y AVG
+124.94%
CURRENT VS 5Y AVG
+433.77%
CURRENT VS 10Y AVG
+1055.49%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.76
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+413.45%
vs the sector median at left
Avalo Therapeutics, Inc.
Market Cap
$714.37M
Current Ratio
19.31
TTM Avg
12.36
3Y Avg
8.58
5Y Avg
3.62
Market Cap
$709.65M
Current Ratio
1.03
TTM Avg
1.26
3Y Avg
1.17
5Y Avg
1.16
Market Cap
$721.69M
Current Ratio
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$723.18M
Current Ratio
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$702.82M
Current Ratio
14.16
TTM Avg
12.98
3Y Avg
15.39
5Y Avg
17.04
Market Cap
$694.79M
Current Ratio
4.48
TTM Avg
5.45
3Y Avg
6.78
5Y Avg
8.00
Market Cap
$693.19M
Current Ratio
19.69
TTM Avg
6.38
3Y Avg
9.16
5Y Avg
11.87
Market Cap
$691.79M
Current Ratio
8.86
TTM Avg
10.22
3Y Avg
11.35
5Y Avg
25.38
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $714.37M | 19.31 | 12.36 | 8.58 | 3.62 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 1.03 | 1.26 | 1.17 | 1.16 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | 0.95 | 4.92 | 2.98 | 5.72 |
| Candel Therapeutics, Inc. (CADL)vs › | $723.18M | 16.09 | 8.04 | 7.87 | 9.13 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | 14.16 | 12.98 | 15.39 | 17.04 |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | 4.48 | 5.45 | 6.78 | 8.00 |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | 9.99 | 4.68 | 3.00 | 2.74 |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | 19.69 | 6.38 | 9.16 | 11.87 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | 8.86 | 10.22 | 11.35 | 25.38 |
| Apnimed, Inc. (APMD)vs › | $742.70M | N/A | N/A | N/A | N/A |
Current Ratio
19.31
Quick Ratio
19.31
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 19.31 |
| 2026-03-31 | 7.66 |
| 2025-12-31 | 8.14 |
| 2025-09-30 | 14.28 |
| 2025-06-30 | 12.44 |
| 2025-03-31 | 22.61 |
| 2024-12-31 | 19.96 |
| 2024-09-30 | 1.42 |
| 2024-06-30 | 0.99 |
| 2024-03-31 | 0.52 |
| 2023-12-31 | 1.82 |
| 2023-09-30 | 2.11 |
| 2023-06-30 | 0.33 |
| 2023-03-31 | 0.83 |
| 2022-12-31 | 0.74 |
| 2022-09-30 | 1.07 |
| 2022-06-30 | 0.98 |
| 2022-03-31 | 2.44 |
| 2021-12-31 | 3.11 |
| 2021-09-30 | 4.04 |
| 2021-06-30 | 2.19 |
| 2021-03-31 | 1.75 |
| 2020-12-31 | 1.71 |
| 2020-09-30 | 2.48 |
| 2020-06-30 | 3.44 |
| 2020-03-31 | 1.66 |
| 2019-12-31 | 1.46 |
| 2019-09-30 | 0.73 |
| 2019-06-30 | 0.74 |
| 2019-03-31 | 0.95 |
| 2018-12-31 | 0.84 |
| 2018-09-30 | 0.74 |
| 2018-06-30 | 0.62 |
| 2018-03-31 | 0.91 |
| 2017-12-31 | 0.96 |
| 2017-09-30 | 5.82 |
| 2017-06-30 | 3.58 |
| 2017-03-31 | 1.26 |
| 2016-12-31 | 1.31 |
| 2016-09-30 | 1.27 |
| 2016-06-30 | 1.99 |
| 2016-03-31 | 2.74 |
| 2015-12-31 | 3.70 |
| 2015-09-30 | 0.51 |
| 2015-06-30 | 1.08 |
| 2015-03-31 | 1.57 |
| 2014-12-31 | 2.44 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 1.35 |
| 2012-12-31 | 6.44 |
